BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/8/2024 7:49:58 AM | Browse: 86 | Download: 282
 |
Received |
|
2024-02-20 06:30 |
|
Peer-Review Started |
|
2024-02-20 06:30 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-04-03 06:06 |
|
Revised |
|
2024-04-12 14:47 |
|
Second Decision |
|
2024-04-25 10:40 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-05-14 03:40 |
|
Articles in Press |
|
2024-05-14 03:40 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-05-28 17:35 |
|
Publish the Manuscript Online |
|
2024-07-08 07:49 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Retrospective Study |
| Article Title |
Dapagliflozin in Heart Failure and Type 2 Diabetes: Efficacy, Cardiac and Renal Effects, Safety
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Pei-Ling Yu, You Yu, Shuang Li, Bai-Chen Mu, Ming-Hua Nan and Min Pang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ming-Hua Nan, MD, Chief Physician, The Second Department of Cardiology, The Second Affiliated Hospital of Liaoning Hospital of Traditional Chinese Medicine, Shenyang 110034, Liaoning Province, China. 18860933@qq.com |
| Key Words |
Heart failure; Type 2 diabetes mellitus; Heart failure with preserved ejection fraction; Myocardial infarction markers; Cardiac function |
| Core Tip |
This study delves into the complex association between type 2 diabetes mellitus (T2DM) and heart failure with preserved ejection fraction (HFrEF), focusing on how the two disorders interact through multiple mechanisms, leading to alterations in cardiac structure and function. Special attention is paid to the role of T2DM in promoting myocardial interstitial fibrosis and decreased cardiac function, and how these alterations exacerbate the course of heart failure, thus providing new perspectives on the treatment of these patients. |
| Publish Date |
2024-07-08 07:49 |
| Citation |
<p>Yu PL, Yu Y, Li S, Mu BC, Nan MH, Pang M. Dapagliflozin in Heart Failure and Type 2 Diabetes: Efficacy, Cardiac and Renal Effects, Safety. <i>World J Diabetes</i> 2024; 15(7): 1518-1530</p> |
| URL |
https://www.wjgnet.com/1948-9358/full/v15/i7/1518.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v15.i7.1518 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
